Lumosa Therapeutics Co., Ltd.

6535

TW0006535008

Biotechnology & Medical Research

End-of-day quote Taipei Exchange Other stock markets 06:00:00 2024-05-02 pm EDT			5-day change	1st Jan Change
170 ^TWD	-1.45%		-1.16%	+148.90%

Apr. 24	Lumosa Therapeutics Co., Ltd. cancelled the transaction announced on May 31, 2023	CI
Apr. 07	GenEditBio Limited announced that it has received funding from Lumosa Therapeutics Co., Ltd., Qiming Weichuang Venture Capital Management Company Limited, Innovation & Technology Fund Company, Hong Kong Science and Technology Parks, Investment Arm	CI

Lumosa Therapeutics Co., Ltd. announced a financing transaction

May 30, 2023

Lumosa Therapeutics Co., Ltd. announced a private placement to issue 70,000,000 common shares on May 31, 2023. The transaction has been approved by shareholders of the company.

Latest news about Lumosa Therapeutics Co., Ltd.

Lumosa Therapeutics Co., Ltd. cancelled the transaction announced on May 31, 2023	Apr. 23	CI
GenEditBio Limited announced that it has received funding from Lumosa Therapeutics Co., Ltd., Qiming Weichuang Venture Capital Management Company Limited, Innovation & Technology Fund Company, Hong Kong Science and Technology Parks, Investment Arm	Apr. 06	CI
Lumosa Therapeutics Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01	CI
Lumosa Therapeutics and CHI Memorial Announce New Study for Acute Stroke	Feb. 02	CI
Lumosa Therapeutics Co., Ltd. Receives Approval to Initiate Phase 2, Multiple-Dose Study of Its LT3001	Jan. 22	CI
Lumosa Therapeutics Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Lumosa Therapeutics Co., Ltd. Approves the Exclusive Licensing Agreement with Gufic Biosciences for LT1001, A Long-Acting Analgesic Injection	Nov. 09	CI
Lumosa Therapeutics Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI
Lumosa Therapeutics Co., Ltd. Approves Formulation Patent for Lumosas Lt3001, A New Drug for Acute Ischemic Stroke	23-07-26	CI
Lumosa Therapeutics Co., Ltd. Appoints Hsin-Jung Lin as Member of the Audit Committee	23-05-31	CI
Lumosa Therapeutics Co., Ltd. Announces Appointment of Hsin-Jung Lin as Independent Director	23-05-31	CI
Lumosa Therapeutics Co., Ltd. announced a financing transaction	23-05-30	CI
Lumosa Therapeutics Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Lumosa Therapeutics Co., Ltd. Appoints Lanying Huang as Corporate Governance Officer	23-05-12	CI
Lumosa Therapeutics Co., Ltd. announced a financing transaction	23-03-09	CI
Lumosa Therapeutics Co., Ltd. Approves Exclusive Licensing Agreement with Pakistan’s AJM Pharma Pvt. Ltd. for LT1001, A Long-Acting Analgesic Injection	22-12-23	CI
Lumosa Therapeutics Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-09	CI
Lumosa Therapeutics Co., Ltd. Approves the Revised Exclusive Licensing Agreement for the Veterinary Analgesic with Skyline Vet Pharma, Inc	22-08-09	CI
Lumosa Therapeutics Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-08	CI
Lumosa Therapeutics Co., Ltd. Approves the Amendments for the Exclusive Licensing Agreement for the Veterinary Analgesic	22-05-31	CI
Lumosa Therapeutics Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-09	CI
LUMOSA Therapeutics Announces TFDA’s Clearance of Phase 2 IND Application for Multiple-Dose of LT3001 in Patients	22-03-24	CI
Lumosa Therapeutics Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-03	CI
Lumosa Therapeutics Announces US FDA Clearance of IND Application for a Phase 2 Multi-Dose Study of LT3001 in Patients with Acute Ischemic Stroke	22-02-09	CI
Lumosa Approves Management Changes, Effective February 1, 2022	22-01-21	CI

Chart Lumosa Therapeutics Co., Ltd.

Duration

Period

More charts

LUMOSA THERAPEUTICS CO., LTD. is a Taiwan-based company principally engaged in the development of new drugs. The Company is engaged in the development of new drugs for unmet medical needs in the fields of central nervous system (CNS), oncology, and inflammatory diseases. The Company is engaged in scientific licensing and new drug development under the reSEARCH and DEVELOPMENT model.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

170 TWD

Average target price

2.28 TWD

Spread / Average Target

-98.66%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
LUMOSA THERAPEUTICS CO., LTD.	+148.90%	869M
REGENERON PHARMACEUTICALS, INC.	+8.96%	105B
VERTEX PHARMACEUTICALS INCORPORATED	-1.43%	104B
ARGENX SE	+4.40%	22.94B
BIONTECH SE	-12.15%	22.34B
GENMAB A/S	-4.36%	19.25B
WUXI APPTEC CO., LTD.	-39.98%	17.08B
BEIGENE, LTD.	-10.04%	16.96B
NEUROCRINE BIOSCIENCES, INC.	+6.79%	14.16B
SAREPTA THERAPEUTICS, INC.	+38.61%	12.63B

Bio Therapeutic Drugs